[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pheochromocytomaparaganglioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pheochromocytomaparaganglioma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,78,153,179,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100645333","phase-2-an-experimental-study-of-belzutifan-impact-on-catecholamine-metabolism-100645333",false,"NCT07680205","An Experimental Study of Belzutifan Impact on Catecholamine Metabolism","An Experimental Pilot Study to Investigate Changes in Catecholamine Synthesis and Metabolism in Patients With Molecularly Profiled Phaeochromocytoma and Paraganglioma Taking Belzutifan","Inclusion Criteria:\n\n* Adult patients \\> 18 years\n* Patients must have a biochemically confirmed diagnosis of a phaeochromocytoma or paraganglioma using plasma metanephrines or 24- hour urinary metanephrines and plasma or urinary metanephrines should be at least 1.5 times the upper limit of the normal reference range.\n* Female patients of child-bearing potential must have a negative serum pregnancy test result within 3 days before first administration of study drug\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Has hypoxia, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.\n* Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft surgery (CABG) ≤6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Medically controlled arrhythmia stable on medication is permitted.\n* Has a co-existing malignancy (in addition to PPGL)\n* Has a Hb \\\u003C 100g\u002FdL\n* Is on medications which may interfere with belzutifan pharmacokinetics and that cannot be stopped for the duration of the study and for 7 days after the study period (everolimus, omeprazole, esomeprazole, Fluconazole, fluoxetine, Voriconazole, Sirolimus)\n* Has a known diagnosis of HIV, hepatitis B or hepatitis C","ALL",{"count":18,"type":19},12,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.",[25,26,27,28,29],"Pheochromocytoma and Paraganglioma (PPGL)","Pheochromocytoma Malignant","Pheochromocytoma, Metastatic","Pheochromocytoma\u002FParaganglioma","Pheochromocytoma",[31,32],"Belzutifan","catecholamine synthesis","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-04-27",{"date":41,"type":19},"2027-12",{"name":43,"class":44},"Cambridge University Hospitals NHS Foundation Trust","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100433434","phase-2-belzutifanmk-6482-for-the-treatment-of-advanced-pheochromocytomaparaganglioma-ppgl-pancreatic-neuroendocrine-tumor-pnet-von-hippel-lindau-vhl-disease-associated-tumors-advanced-gastrointestinal-stromal-tumor-wt-gist-or-solid-tumors-with-hif-2-related-genetic-alterations-mk-6482-015-100433434","NCT04924075","Belzutifan\u002FMK-6482 for the Treatment of Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations","The main inclusion criteria include but are not limited to the following:\n\n* Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)\n* Diagnosis of one of the following: Advanced\u002Fmetastatic pheochromocytoma\u002Fparaganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations\n* Cohort B1: VHL Disease-associated tumors:\n\n  * Have a diagnosis of VHL disease as determined by a germline test locally and\u002For clinical diagnosis\n  * Must be ≥18 years of age\n* Has a life expectancy of at least 3 months\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan\n* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years\n* Any of the following: A pulse oximeter reading \\\u003C92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen\n* Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure\n* Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention","12 Years",{"count":55,"type":19},355,[22],"This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma\u002Fparaganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).",[28,59,60,61,62],"Pancreatic Neuroendocrine Tumor","Von Hippel-Lindau Disease","Advanced Gastrointestinal Stromal Tumor","HIF-2α Mutated Cancers",[64,65,66],"HIF-2α","Pheochromocytoma\u002Fparaganglioma","Pancreatic NET","2026-06-24",{"date":69,"type":37},"2026-06-26",{"date":71,"type":37},"2021-08-12",{"date":73,"type":19},"2029-12-27",{"name":75,"class":76},"Merck Sharp & Dohme LLC","INDUSTRY",84,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":134,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631","NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.",{"count":86,"type":19},1500,"OBSERVATIONAL","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,28,128,129,130,131,132,133,60],"Acute Leukemia","Adenomatous Polyposis","Adrenocortical Carcinoma","AML","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Familial Adenomatous Polyposis","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Hodgkin Lymphoma","Juvenile Polyposis","Li-Fraumeni Syndrome","Lynch Syndrome","MDS","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Non Hodgkin Lymphoma","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Pancreatic Cancer","Peutz-Jeghers Syndrome","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rhabdomyosarcoma","Rothmund-Thomson Syndrome","Tuberous Sclerosis",[135,136,137,138,139,140,141,142,143],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","2026-06-15",{"date":146,"type":37},"2026-06-17",{"date":148,"type":37},"2017-04-06",{"date":150,"type":19},"2037-03-31",{"name":152,"class":44},"St. Jude Children's Research Hospital",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":45},"100638922","a-comparison-of-68gadotatate-and-18fambf3tate-for-the-staging-and-assessment-of-neuroendocrine-malignancies-100638922","NCT07621146","A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies","A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study","NET-COMPARE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients referred for and meeting institutional criteria for a \\[68Ga\\]DOTATATE PET\u002FCT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).\n\nExclusion Criteria:\n\n* Pregnant and breast-feeding patients.\n* Patients unwilling or unable to undergo a second PET\u002FCT.\n* Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET\u002FCT bore (70cm diameter).","18 Years",{"count":163,"type":19},51,"Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.",[166,28,167,168],"Neuroendocrine Tumors, NET","SSTR-expressing Tumors","Medullary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-27",{"date":172,"type":37},"2026-06-02",{"date":174,"type":19},"2026-09-15",{"date":176,"type":19},"2028-03",{"name":178,"class":44},"British Columbia Cancer Agency",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":20,"phases":190,"briefSummary":191,"conditions":192,"keywords":200,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":45},"100605808","phase-2-real-world-effectiveness-and-pharmacogenetics-of-belzutifan-in-vhl-syndrome-the-believe-vhl-trial-100605808","NCT07167329","Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial","The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan","BELIEVE-VHL","Inclusion Criteria:\n\n* Age ≥ 14 years.\n* Clinical or genetic confirmation of von Hippel-Lindau (VHL) syndrome.\n* Presence of measurable or progressive VHL-associated tumors, as defined by RECIST 1.1 or disease-specific imaging criteria.\n* ECOG performance status of 0-2.\n* Adequate bone marrow, hepatic, and renal function as defined by laboratory reference values.\n* Ability to swallow oral medication.\n* Provision of written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Age \\\u003C 14 years.\n* Absence of a confirmed diagnosis of von Hippel-Lindau (VHL) syndrome.\n* Presence of an active malignancy outside the VHL tumor spectrum within the past 3 years, except for adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies considered cured for \\>2 years.\n* Known hypersensitivity or allergic reaction to belzutifan or any excipient in the formulation.\n* History of severe or uncontrolled cardiovascular disease, including but not limited to unstable angina, myocardial infarction within the past 6 months, congestive heart failure requiring treatment, or uncontrolled hypertension.\n* Active infectious diseases, including HIV, hepatitis B, or hepatitis C.\n* Immunosuppressed status, whether due to underlying disease or ongoing therapy.\n* History of significant bleeding disorders, including bleeding diathesis, thrombocytopenia, or coagulopathy.\n* Radiotherapy administered within 4 weeks prior to study enrollment.\n* Major surgical procedure, including for VHL-related tumors, within 4 weeks prior to study enrollment, or immediate need for surgical intervention for tumor management.\n* Malabsorption secondary to prior gastrointestinal surgery or active gastrointestinal disease.\n* Current use of concomitant medications known to interact with belzutifan and significantly alter its bioavailability.\n* Anticipated low adherence to or planned interruption of belzutifan therapy.","14 Years",{"count":189,"type":19},100,[22],"The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.",[193,194,195,196,197,198,28,199],"Von Hippel Lindau","Von Hippel Lindau Disease","Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma","Hemangioblastoma (HB) of the Central Nervous System (CNS)","PNET","Retinal Angiomatous Proliferation","Endolymphatic Sac Tumor",[31,201,202,203,204],"von Hippel-Lindau","Renal Cell Clear Carcinoma","Hemangioblastoma of Central Nervous System","Pharmacogenetics","2025-09-09",{"date":207,"type":37},"2025-09-11",{"date":209,"type":37},"2024-01-01",{"date":211,"type":19},"2030-01-01",{"name":213,"class":44},"José Claudio Casali da Rocha",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":20,"phases":223,"briefSummary":224,"conditions":225,"keywords":243,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":45},"100568639","phase-2-ivonescimab-in-the-treatment-of-multiple-advanced-tumors-100568639","NCT06683846","Ivonescimab in the Treatment of Multiple Advanced Tumors","Ivonescimab (PD-1\u002FVEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study","Inclusion Criteria:\n\n* Individuals able to understand and give written informed consent.\n* Histologically or cytologically confirmed cancer of one of the following types:\n\nPAGET's disease of scrotum with infiltrating sweat gland carcinoma Paraganglioma Pheochromocytom, Renal angiomyolipoma Malignant perivascular epithelioid cell tumor, Rhabdomyosarcom Other sarcoma rather than rhabdomyosarcom\n\n* Stage IV disease\n* Adequate performance status (ECOG 0-2)\n* Expected survival ≥ 3 months.\n* Measurable disease by CT or MRI, Or lesions with skin infiltration.\n* Adequate hematology without ongoing transfusional support (hemoglobin \\> 9 g\u002FdL, absolute neutrophil count (ANC) \\> 1,500 per mm\\^3, platelets \\> 100,000 per mm\\^3).\n* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).\n* Adequate coagulation function: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN.\n* Willing to use a medically approved contraceptive method from the enrollment to at least 120 days after the end of the study, and sperm donation to another person or cryopreservation for fertilization and reproduction is not permitted during this period.\n* Ability to comply with research visit schedules and other protocol requirements.\n\nExclusion Criteria:\n\n* With any severe and\u002For uncontrolled disease. Including: (1)Poor blood pressure control (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg); (2) poor control of diabetes (fasting blood sugar \\[FBG\\] \\>10mmol\u002FL);\n\n  ≥2 grade myocardial ischemia or myocardial infarction, arrhythmia (QTc≥470ms), and ≥2 grade congestive heart failure (NYHA classification); (3)active or uncontrolled severe infections requiring systemic antibacterial, antifungal, or antiviral treatment (≥CTCAE 2-level infection), including tuberculosis infection; A history of active tuberculosis; (4)Uncontrolled ascites, pleural effusion, or pericardial effusion that require repeated drainage;\n* With active hepatitis (transaminase levels not meeting inclusion criteria; HBV reference: HBV DNA≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; HCV reference: HCV RNA≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; after nucleoside analog antiviral therapy below the above standard, can be included; chronic hepatitis B virus carrier, HBV DNA\\\u003C10\\^4 IU\u002Fml, must be treated with antiviral drugs during the trial period to be eligible for enrollment);\n* History of immunodeficiency, including HIV positive or subjects with other acquired or congenital immunodeficiency diseases;\n* Active autoimmune disease requiring systemic treatment within the past two years, or subjects with an autoimmune disease that the investigator judges may recur or is planned for treatment; except: non-systemic treatment of skin diseases (e.g. vitiligo, alopecia, psoriasis or eczema); autoimmune thyroiditis-induced hypothyroidism requiring stable dose replacement therapy with hormones; 13. Subjects who have experienced severe hypersensitivity reactions after using monoclonal antibodies; individuals who are known to be allergic to the active ingredients or excipients of the study drug;\n* Have participated or are currently participating in another clinical study within the past 4 weeks prior to study entry;\n* Received a live vaccine within the past 30 days prior to the first dose or plan to receive a live vaccine during the study;\n* History of severe allergies;\n* At risk of bleeding, or with impaired coagulation function, or currently receiving thrombolytic therapy;\n* History of substance abuse with an inability to abstain or a history of mental illness;\n* Subjects who, in the opinion of the investigator, have a serious underlying condition that would endanger the subject's safety or impair the subject's ability to complete the study, or who, in the opinion of the investigator, have other reasons not to be enrolled; Subjects who have a history of a clearly defined neurological or psychiatric disorder, such as dementia, epilepsy, or a history of seizure susceptibility;\n* Subjects who, in the opinion of the investigator, have a serious underlying condition that would endanger the subject's safety or impair the subject's ability to complete the study (such as severe diabetes, thyroid disorders, and mental illness), or who have a serious and\u002For unstable medical, psychological, or other condition (including laboratory abnormalities) that would affect the subject's safety or the subject's ability to provide informed consent, or who have any condition that would affect the study protocol and follow-up plan, including psychological, familial, social, or geographic factors;",{"count":222,"type":19},400,[22],"The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma. cohort 2: Metastatic paraganglioma and pheochromocytoma. cohort 3: Metastatic renal angiomyolipoma and malignant perivascular epithelioid cell tumor.\n\ncohort 4: Rhabdomyosarcoma and Ewing's sarcoma cohort 5: Collecting duct carcinoma cohort 6: Urachal carcinoma. cohort 7: Neuroendocrine cancer. cohort 8: Basal cell carcinoma and sarcomatoid carcinoma. cohort 9: Penile cancer. cohort 10: Adrenal cortical cancer. cohort 11: Metastatic germ cell tumors, failure of standard cisplatin based therapy (mostly testicular cancer).\n\ncohort 12: Non-clear cell renal carcinoma (including renal papillary renal carcinoma); Renal cancer cannot be classified).\n\ncohort 13: Non-clear cell renal carcinoma (including chromophobe renal carcinoma) cohort 14: Other rare tumors that cannot be classified (such as testicular reticulum adenocarcinoma, etc.).\n\ncohort 15: Prostate cancer. cohort 16: Clear cell renal carcinoma. (16.1: received PD-1; 16.2: no PD-1 received) cohort 17: Urothelial carcinoma. cohort 18: Kidney cancer with brain metastases. cohort 19: Brain metastases of urothelial carcinoma. cohort 20: Rare tumors with brain metastases.\n\nIt will also learn about the safety of Ivonescimab. The main questions it aims to answer are:\n\nDoes Ivonescimab improve the objective response rate and prolong the survival of participants? What medical problems do participants have when taking Ivonescimab?\n\nParticipants will:\n\nReceive Ivonescimab 20mg\u002Fkg intravenously every 21 days until disease progression, intolerable toxicity, or full 2 years of treatment, whichever occurs first.\n\nBe performed imaging evaluation according to RECIST 1.1 every 9 weeks for 1 year of treatment and every 12 weeks after 1 year Be recorded any adverse events in the whole study period including type, incidence, grade, severity, duration, and association with the study drug according to NCI-CTCAE V5.0 criteria",[28,131,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242],"Paget Disease, Extramammary","Renal Angiomyolipoma","Perivascular Epithelioid Cell Tumor, Malignant","Sarcoma","Urachal Cancer","Neuroendocrine Cancer","Basal Cell Carcinomas","Sarcomatoid Carcinoma","Penile Cancer","Adrenal Cortical Cancer","Germ Cell Cancer Metastatic","Non-Clear Cell Renal Cell Carcinoma","Prostate Cancers","Clear Cell Renal Cancer","Urothelial Carcinoma","Kidney Cancer","Rare Tumors",[244,245,246],"rare tumor","Ivocizumab","immunotherapy","2025-08-19",{"date":249,"type":37},"2025-08-24",{"date":251,"type":37},"2024-11-20",{"date":253,"type":19},"2027-11-30",{"name":255,"class":44},"Fudan University"]